SG Americas Securities
CMPX icon

SG Americas Securities’s Compass Therapeutics CMPX Stock Holding History

SG Americas Securities’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$252K Sell
47,670
-58,863
-55% -$340K ﹤0.01% 2537
2025
Q4 		$572K Sell
106,533
-42,780
-29% -$198K ﹤0.01% 2412
2025
Q3 		$523K Sell
149,313
-223,368
-60% -$706K ﹤0.01% 2073
2025
Q2 		$969K Sell
372,681
-568,103
-60% -$1.17M ﹤0.01% 1202
2025
Q1 		$1.79M Buy
940,784
+545,767
+138% +$1.45M 0.01% 839
2024
Q4 		$573K Buy
395,017
+356,352
+922% +$592K ﹤0.01% 1207
2024
Q3 		$71K Buy
38,665
+5,515
+17% +$6.87K ﹤0.01% 3166
2024
Q2 		$33K Buy
33,150
+4,409
+15% +$6.44K ﹤0.01% 2733
2024
Q1 		$57K Sell
28,741
-18,883
-40% -$32.6K ﹤0.01% 2722
2023
Q4 		$74K Buy
47,624
+8,817
+23% +$15.3K ﹤0.01% 2845
2023
Q3 		$76K Buy
+38,807
New +$96K ﹤0.01% 2859

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SG Americas Securities's CMPX Position: Q1 2026 in Review

SG Americas Securities reduced its Compass Therapeutics (CMPX) stake by 55% in Q1 2026, selling an estimated $340K and leaving 47,670 shares worth $252K. The position accounts for ﹤0.01% of the portfolio, ranked #2537.

SG Americas Securities first reported a position in CMPX in Q3 2023 and has held it in 11 quarters since. The position peaked at $1.79M in Q1 2025. 201 funds tracked by Wall St. Rank hold CMPX as of Q1 2026.

  • SG Americas Securities held 47,670 shares of Compass Therapeutics worth $252K as of Q1 2026.
  • SG Americas Securities sold 58,863 Compass Therapeutics shares in Q1 2026, an estimated $340K.
  • Compass Therapeutics made up ﹤0.01% of SG Americas Securities's portfolio in Q1 2026, its #2537 holding.
  • SG Americas Securities first reported a position in Compass Therapeutics in Q3 2023 and has held it in 11 quarters since.
  • SG Americas Securities's Compass Therapeutics position peaked at $1.79M in Q1 2025.
  • 201 funds tracked by Wall St. Rank held Compass Therapeutics as of Q1 2026.

Based on SG Americas Securities's 13F filing for Q1 2026, filed 16 Apr 2026.